Indeed, the GR antagonist RU486 (mifepristone) is currently being registered in 10 clinical trials for breast cancer (NCT02788981, NCT05062174, NCT01138553, NCT01493310, NCT01898312, NCT02014337, NCT02046421, NCT02651844, NCT03225547, NCT05016349), among which 4 are completed, 1 is active, not-recruiting, 2 are not yet recruiting, and 1 has been terminated (Table 2, Online Resource 1). This evidence concerns the gene NR3C1 and breast carcinoma.